

# The International Rare Diseases Research Consortium (IRDiRC)



The Scientific Secretariat of IRDiRC is supported by the European Union through the European Joint Programme on Rare Diseases under the European Union's Horizon 2020 Research and Innovation Programme Grant Agreement N°825575.

## **International Rare Diseases Research Consortium**

- History
- Vision and Goals
- Members
- Governance and Operating Model
- Task Forces and Working Groups
- Publications, News and Events
- State-of-Play Reports
- Recognized Resources
- Get involved



## **History**

IRDIRC was founded in 2011 to accelerate breakthroughs in rare diseases by coordinating research funding

2012

 Open Calls for **New Members:** ongoing basis ever since

2015

**Establishment** tackle specific rare disease research topics Today IRDIRC has tripled in size

Today '

2017

**New Strategic Vision** 

people living with a

receive an accurate

diagnosis, care, and

available therapy

within one year of

coming to medical

attention"

2027: "Enable all

rare disease to

Numerous peer reviewed publications, recommendations and guidelines to expediate research and innovation

**Driving force is the sharing** of collective intelligence in a non-competitive space

2011

 Official launch of IRDIRC with two • 1<sup>st</sup> workshop in goals: "to contribute Iceland organized to the development by the European of diagnostic tools Commission and for most RDs and of **US National** 200 new therapies Institutes of by 2020" Health

of Task Forces to



2010


## **IRDiRC Strategic Vision**

"Enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention."

## **IRDiRC Goals by 2027**



## **IRDiRC Thematic Research Actions**





# Members collaborate, stimulate, coordinate, and leverage output of rare diseases research efforts around the world

- 60 member organizations and over 100 experts
- Unite research funders and companies investing in RD research
  - Each organization funds research its own way
  - Funded projects adhere to a common framework
- Umbrella patient advocacy groups
- 4 Scientific Committees
  - Diagnostics
  - Therapies
  - Interdisciplinary
  - Regulatory

Research Funders

- Collective Intelligence
- Global Expertise
- ComplementaryCompetencies




IRDiRC actors

**Companies** 

Patient Advocate Groups Driver of International Initiatives



## **Governance and Operating Model**





## **Task Forces & Working Groups**

Task Forces (TFs) and Working Groups (WGs) are the instruments adopted by IRDiRC to address actionable topics identified by the Consortium and reflecting the evolving priorities for RDs.

#### **Task Force**

Time limited: 12-18 months.

Objectives and scope: Clearly pre-defined.

**Commitment:** Monthly conference calls

and in-person meeting.

Composition: Leverage on the expertise of

internal and external experts.

Output: Recommendation paper, technical

application.

#### **Working Group**

Time limited: 6-9 months.

Objectives and scope: Exploratory work. Commitment: Monthly conference calls.

Composition: Leverage on the expertise of

internal and external experts.

Output: Recommendation paper, IRDiRC

report.



## **Publications, News and Events**

IRDiRC has developed RD community engagement instruments to present its activities, provide a forum for discussions and influence global RD research.



Recommendations, tools or guidelines by TFs and WGs, and IRDiRC reviews and commentaries are published as peer-reviewed articles or IRDiRC reports.



Dissemination via the IRDiRC website, newsletters, social media and member/partner channels effectively widens awareness and influence beyond the RD community.



Biannual conference engaging researchers, clinicians, patient advocates, industry leaders and policy makers from all continents.



https://irdirc.org/activities/irdirc-publications/ https://irdirc.org/news/

https://irdirc.org/news-events/irdirc-newsletters-social-media/

## **State-of-Play Reports**



**State-of-Play Reports** aim to inform stakeholders at large of developments in the field of rare diseases research in order to support decisions of policy makers and research funders. At the same time, the report is focused on informing the rare diseases community at large of the achievements and of observed trends, which shape the future of research and development for rare diseases.

It is based on a systematic survey of published articles, in scientific journals and press releases.



## **Recognized Resources**



**IRDirC Recognized Resources** label is a **quality indicator**, based on a specific set of criteria, created to highlight key resources which, if used more broadly, would **accelerate the pace of translating discoveries into clinical applications**.

Any resource compliant with the criteria may apply for the label. Selected platforms, tools, standards, and guidelines must be of **fundamental importance** to the international rare diseases research and development community.



### **Get involved**

# Become a Member Funders and Companies

The organization should invest in rare disease R&D for minimum USD 10 million over a 5-year period.

It includes expenses associated with the organization's internal and/or third-party RD innovation and improvements.

The organization should complete the Letter of Intent and send it to the Scientific Secretariat of IRDiRC.

# Become a Member Patient Umbrella Groups

The group should represent patients with different rare diseases (umbrella group) and cover a large region or country.

The organization should complete the Letter of Intent and send it to the Scientific Secretariat of IRDiRC.

#### **Scientific Contribution**

External experts can apply to become member of one of the IRDiRC Scientific Committees and/or to join a Task Force. Candidates should send their CV, a biosketch and a letter of motivation to the Scientific Secretariat of IRDiRC. Candidates will be contacted based on the specific needs of IRDiRC Scientific Committees and Task Forces.





The Scientific Secretariat of IRDiRC is supported by the European Union through the European Joint Programme on Rare Diseases under the European Union's Horizon 2020 Research and Innovation Programme Grant Agreement N°825575.